Press coverage about ZIOPHARM Oncology (NASDAQ:ZIOP) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. ZIOPHARM Oncology earned a news impact score of 0.24 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 46.0921995095477 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

A number of brokerages have commented on ZIOP. BidaskClub lowered ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a report on Monday, August 14th. ValuEngine lowered ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a report on Friday, September 15th. Finally, HC Wainwright set a $10.00 price objective on ZIOPHARM Oncology and gave the company a “buy” rating in a report on Tuesday, August 1st. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $13.17.

ZIOPHARM Oncology (ZIOP) opened at 6.14 on Friday. The firm’s market capitalization is $863.48 million. ZIOPHARM Oncology has a one year low of $4.84 and a one year high of $7.88. The firm has a 50-day moving average price of $5.85 and a 200-day moving average price of $6.25.

ZIOPHARM Oncology (NASDAQ:ZIOP) last released its earnings results on Monday, July 31st. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.13). The firm had revenue of $1.60 million during the quarter, compared to analysts’ expectations of $1.66 million. During the same period in the prior year, the business earned ($1.01) earnings per share. The business’s quarterly revenue was down 5.9% compared to the same quarter last year. Analysts expect that ZIOPHARM Oncology will post ($0.56) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://theolympiareport.com/2017/09/30/ziopharm-oncology-ziop-getting-somewhat-positive-press-coverage-analysis-finds.html.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Insider Buying and Selling by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)

Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.